Clinical and experimental rheumatology · 2026
Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biard Lucie, Pugnet Grégory, Cacciatore Carlotta, Prata Pedro Henrique, Crichi Benjamin, Urbain Fanny, Munia Ingrid, Lansiaux Pauline, Le Maignan Christine, Farge Dominique
Аннотация
OBJECTIVES: This study aimed to evaluate the effectiveness of the SARS-CoV-2 vaccination program in systemic sclerosis (SSc) patients treated by Autologous Haematopoietic Stem Cell Transplantation (AHSCT) compared to non-AHSCT SSc patients.
METHODS: A French retrospective case-control study was conducted in SSc patients eligible for SARS-CoV-2 vaccination. AHSCT SSc (cases) were matched 1:1 with non-AHSCT SSc (controls) patients by age, sex, and disease duration. The primary endpoint was to assess the cumulative incidence of COVID-19 infection. Secondary objectives evaluated vaccination acceptance, the onset of severe adverse events after SARS-CoV-2 vaccination, the severity of COVID-19 infection and the serological response after vaccination or not.
RESULTS: Seventy-two SSc patients (36 AHSCT 1:1 matched to 36 non-AHSCT, on age, sex, and disease duration on 1 January 2021) were included. The study showed a higher incidence of COVID-19 infection in AHSCT (p=0.007) versus non-AHSCT SSc patients, with respectively 11 out 36 cases and 2 out 36 controls contracting mild to moderate infections. The vaccine acceptance rate did not differ between AHSCT and non-AHSCT SSc patients, with respectively 5 out 36 cases and 3 out 36 controls who refused vaccination. No severe adverse event was reported after SARS-Cov-2 vaccination. Serological responses did not significantly differ between the two groups.
CONCLUSIONS: The incidence of COVID-19 infection was higher in AHSCT-SSc compared to non-AHSCT SSc patients, with no difference in vaccine acceptance rate. COVID-19 vaccination in AHSCT highly fragile patients appeared to provide substantial COVID-19 protection, as shown by their favourable clinical evolution and effective humoral response.
METHODS: A French retrospective case-control study was conducted in SSc patients eligible for SARS-CoV-2 vaccination. AHSCT SSc (cases) were matched 1:1 with non-AHSCT SSc (controls) patients by age, sex, and disease duration. The primary endpoint was to assess the cumulative incidence of COVID-19 infection. Secondary objectives evaluated vaccination acceptance, the onset of severe adverse events after SARS-CoV-2 vaccination, the severity of COVID-19 infection and the serological response after vaccination or not.
RESULTS: Seventy-two SSc patients (36 AHSCT 1:1 matched to 36 non-AHSCT, on age, sex, and disease duration on 1 January 2021) were included. The study showed a higher incidence of COVID-19 infection in AHSCT (p=0.007) versus non-AHSCT SSc patients, with respectively 11 out 36 cases and 2 out 36 controls contracting mild to moderate infections. The vaccine acceptance rate did not differ between AHSCT and non-AHSCT SSc patients, with respectively 5 out 36 cases and 3 out 36 controls who refused vaccination. No severe adverse event was reported after SARS-Cov-2 vaccination. Serological responses did not significantly differ between the two groups.
CONCLUSIONS: The incidence of COVID-19 infection was higher in AHSCT-SSc compared to non-AHSCT SSc patients, with no difference in vaccine acceptance rate. COVID-19 vaccination in AHSCT highly fragile patients appeared to provide substantial COVID-19 protection, as shown by their favourable clinical evolution and effective humoral response.